The company acquired exclusive distribution rights with new principal from EU and began distributing two new niche medicines, for treatment of patients with acute lymphoblastic leukaemia (ALL) and an antiviral agent with broad spectrum activity inhibiting the human virus of the herpes group, including HIV at concentrations not affecting cell growth. We identified a potential shortage of antivenom serum in the EU markets and established cooperation with the Institute of Virology, Vaccines, and Sera “Torlak”. We successfully exported their product VIEKVIN® to the markets of Germany, Austria, and Italy and incorporated the entire Torlak portfolio into our offering. We commenced with activities and projects to expand cooperation in other markets.
